Patients with migraine, patent foramen ovale (PFO), and atrial septal aneurysm (ASA) have more frequent ischemic brain lesions, migraine with aura, and larger PFO sizes than patients with migraines and PFO without ASA, according to the results of a recent study.
Patients with migraine, patent foramen ovale (PFO), and atrial septal aneurysm (ASA) have more frequent ischemic brain lesions, migraine with aura, and larger PFO sizes than patients with migraines and PFO without ASA, according to the results of a recent study.
PFO is an interatrial opening that did not close up during infancy, and although the occurrence of PFO is not rare in the general population (27%), its prevalence is nearly doubled in patients with migraine with aura (48%). ASA is another heart deformity where the atrial septum bulges into the right or left atrium. The prevalence of ASA is rare (2%-3%) but occurs significantly more frequently in the presence of PFO.
Although the effects of ASA are not fully understood, its incidence has been identified as one of the risk factors for cryptogenic stroke. Because patients with migraine are more predisposed to PFO, their risk of ASA also increases. To analyze this connection further, researchers conducted a retrospective study on patients with migraine and PFO and its association with ASA.
In this study, patients with migraine and PFO were divided into 2 groups: group A for patients with ASA and group B for patients without ASA. Baseline characteristics were similar between the 2 groups; however, patients in group A had increased frequency of ischemic brain lesions (11.3% vs 6.2%, P = .038), migraines with aura (32.5% vs 21.1%, P = .040), and significantly larger PFO size (median size; 2.6 mm vs 2.1 mm, P = .007).
All patients underwent PFO closure either through Cardi-O-Fix PFO occluder or Amplatzer PFO occluder. The procedure was successful in all the patients, with no patients experiencing transient ischemic attacks or stroke afterward. Two patients did develop paroxysmal atrial fibrillation: 1 reverted spontaneously and 1underwent pharmacological conversion.
To analyze the differences in migraine severity, investigators used the headache impact test-6 (HIT-6). Prior to surgery, baseline HIT-6 scores were 61 and 63 for groups A and B, respectively. At the 1-year follow up, the average HIT-6 scores were 36 were both groups, indicating a drastic decrease from baseline. No significant differences before and at the 1-year follow up after the PFO closure were seen between the 2 groups.
Based on the findings, investigators concluded that the prevalence of ASA in patients with migraines and PFO is associated with silent stroke, larger PFO size, and migraines with aura. However, due to similar HIT-6 scores between the 2 groups, there does not seem to be differences in the severity of the migraines.
Reference:
He L, Cheng G, Du Y, Zhang Y. Clinical relevance of atrial septal aneurysm and patent foramen ovale with migraine. World J Clin Cases. 2018;6(15):916-921. doi: 10.12998/wjcc.v6.i15.916.
Optimizing Episodic Migraine Care: ACP’s Latest Treatment Guidance
February 3rd 2025With historical data showing migraine to be underdiagnosed and undertreated, new guidance from the American College of Physicians (ACP) encompasses 3 recommendations on treating episodic migraine in adult patients in the outpatient setting.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
Care for Migraine Insufficient in Germany, Online Survey Finds
March 25th 2022An online survey of migraineurs in Germany aimed to evaluate their most pressing unmet needs, with data collected on socioeconomic background, medical care experience, acute medication use, and migraine prophylaxis use and experience.
Read More
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen